Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,881 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Diseases Clear all
Completed Phase 4 Interventional Results available

Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation

NCT00629122
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A), Nystatin Suspension
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 15, 2026, 6:25 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873
View directory record Official record
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
114
States / cities
Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 15, 2026, 6:25 PM EDT
Recruiting Not applicable Interventional

SPYRAL GEMINI Pilot Study

NCT06907147
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Multi-Organ Denervation Gemini System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 15, 2026, 6:25 PM EDT
Completed No phase listed Observational

Sex Hormone and Vascular Function in Women With CKD

NCT05471518
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
51 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 15, 2026, 6:25 PM EDT
Withdrawn No phase listed Observational

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

NCT04782297
View directory record Official record
Conditions
CKD, ESRD
Interventions
Long term hemodialysis catheter
Device
Lead sponsor
Medical Components, Inc dba MedComp
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 15, 2026, 6:25 PM EDT
Terminated Not applicable Interventional

ProStat Supplementation in Dialysis Patients

NCT00435123
View directory record Official record
Conditions
Malnutrition, ESRD
Interventions
Nutritional Supplement ProStat 64 twice a day, Placebo supplement
Dietary Supplement
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Wichita, Kansas • Springfield, Massachusetts • Columbus, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional Results available

Vitamin D and Arteriovenous Fistulae

NCT00912782
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 3 Interventional Results available

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

NCT00500682
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Placebo, AST-120
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Alhambra, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 15, 2026, 6:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

NCT03803423
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
The Donor App
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
6
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional Results available

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions

NCT02059005
View directory record Official record
Conditions
Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
Interventions
Specialized Community Disease Management, Treatment As Usual
Behavioral
Lead sponsor
Treatment Research Institute
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 15, 2026, 6:25 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional Results available

Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication

NCT05154773
View directory record Official record
Conditions
End-stage Renal Disease, Chronic Kidney Diseases
Interventions
Kidney donation and transplant information made easy
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
Not listed
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional

Diabetes CKD Lifestyle Technology Study

NCT02266823
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes, Obesity
Interventions
Social Cognitive Theory
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional Results available

Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease

NCT04019379
View directory record Official record
Conditions
Phosphorus and Calcium Disorders, Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Diseases
Interventions
High Phosphorus Diet, Low Phosphorus Diet
Other
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 6:25 PM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

NCT03947970
View directory record Official record
Conditions
Hemodialysis, Healthy
Interventions
[14C] CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ertapenem
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 88 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 15, 2026, 6:25 PM EDT
Terminated Not applicable Interventional Results available

Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD

NCT02975505
View directory record Official record
Conditions
Chronic Kidney Disease, Bloodpressure, Hypertension
Interventions
Strict blood pressure control
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Not applicable Interventional

Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients

NCT01776073
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Patient Navigation
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 3 Interventional Results available

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466
View directory record Official record
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 15, 2026, 6:25 PM EDT
Completed No phase listed Observational

Sickle Cell Uric Acid (SCUA) - Cohort Repository

NCT04190888
View directory record Official record
Conditions
Chronic Kidney Diseases, Sickle Cell Disease
Interventions
No intervention
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
5 Years to 29 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 15, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 15, 2026, 6:25 PM EDT